Oncolix, Inc. Stock Price - ONCX

Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Ultimate Trader
Monthly Subscription
for only
$80.29
VAT not included
Company Name Stock Ticker Symbol Market Type
Oncolix, Inc. (QB) ONCX OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.0001 0.0001 0.0001 0.0001 0.0001 07:29:08
Bid Price Ask Price Spread Spread % News
0.0001 0.0001 0.00 0.0% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1 4,900,000 $ 0.0001 $ 490 800,410 0.000001 - 0.0189
Last Trade Time Type Quantity Stock Price Currency
15:21:34 4,900,000 $ 0.0001 USD

Oncolix, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 205.47k 2.05B $ -3.36M - - 26.78M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
200.00k $ - 0.00% - -

more financials information »

Oncolix, Inc. News

Loading Messages....

Latest ONCX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONCX Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.00010.00010.0000010.00014M0-
1 Month0.00010.00010.0000010.00012M0-
3 Months0.00010.00010.0000010.00012M0-
6 Months0.00010.00010.0000010.00014M0-
1 Year0.0150.01890.0000010.000929M-0.0149-99.33%
3 Years0.320.340.0000010.00299M-0.3199-99.97%
5 Years0.26550.359850.0000010.00298M-0.2654-99.96%

Oncolix, Inc. Description

Oncolix is a clinical-stage biopharmaceutical company developing medical therapies for the treatment of cancer. Prolanta, covered by eight US and additional foreign patents, has two potential mechanisms of action - autophagy and prevention of chemoresistance. Our initial focus is the development, clinical testing and commercialization of Prolanta for the treatment of ovarian cancer. The FDA has provided clearance to commence a Phase 1 clinical trial of Prolanta in the treatment of ovarian cancer, which is now in progress. The FDA has granted Prolanta status as an Orphan Drug, providing potential tax benefits and market exclusivity. After completion of the Phase 1 study, we intend to conduct additional clinical trials in larger numbers of ovarian cancer patients to establish safety and efficacy. Oncolix will evaluate the use of Prolanta in combination with other chemotherapy drugs such as platinum-based drugs and taxanes. Prolanta has the potential to treat other cancers, including breast, endometrial and cervical. These studies may be performed in collaboration with larger pharmaceutical companies, either through licenses or joint ventures. Our scientific collaborators have demonstrated in animal models the efficacy of Prolanta in treating breast cancer, and we intend to engage academic collaborators to develop data for the treatment of other cancer types. Oncolix is also evaluating in-licensing or acquisition of other drug candidates, preferably in oncology.


Your Recent History
USOTC
ONCX
Oncolix, I..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.